Navigation Links
Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights
Date:4/23/2009

ANA773 and two receiving placebo in each cohort. There was a statistically significant decrease in viral load in the group dosed at 1600 mg compared to placebo, although not all patients at this dose demonstrated a decrease in viral load. One patient at 1600 mg demonstrated a nadir response of 0.8 log10 decline with an end-of-treatment response of 0.7 log10; a second patient demonstrated a nadir response of 1.1 log10 decline and an end-of-treatment response of 0.5 log10; and a third patient demonstrated a nadir response of 2.5 log10 decline and an end-of-treatment response of 2.2 log10. No serious adverse events have been reported and there were no discontinuations from the patient portion of this study. In an earlier segment of the study, dosing in healthy volunteers showed evidence of immune induction starting at 800 mg. Tolerability in healthy volunteers was generally good, with no serious adverse events. An increased incidence of interferon-like side effects was seen at the 1200 and 1600 mg dose levels, with one discontinuation at 1200 mg and two discontinuations at 1600 mg. The pharmacokinetic (PK) and pharmacodynamic (PD) data from the healthy volunteer portion of the Phase I Clinical Trial of ANA773 in HCV are being presented in a poster at EASL titled, "PK/PD Assessment of a Phase I Healthy Volunteer with ANA773, an Oral Inducer of Endogenous Interferons that Acts Via TLR7, for the Treatment of HCV."

  • Phase I Clinical Trial in Oncology. Anadys continues to enroll patients in a Phase I study of ANA773 in oncology. The Company is currently dosing ANA773 at 800 mg, administered every other day.

Webcast of Conference Call

Anadys will host a conference call at 5:00 pm Eastern Daylight Time today to discuss its first quarter 2009 financial results and highlights and to provide an update on its deve
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
2. Anadys Pharmaceuticals to Report Third Quarter 2007 Financial Results
3. Anadys Pharmaceuticals to Present at the Acumen BioFin Rodman & Renshaw Healthcare Conference
4. Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
5. Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
6. Anadys Pharmaceuticals to Present at the JPMorgan Healthcare Conference
7. Anadys Pharmaceuticals to Present at the BIO CEO & Investor Conference
8. Anadys Pharmaceuticals to Report Fourth Quarter and Year-End 2007 Financial Results
9. Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference
10. Anadys Pharmaceuticals Commences Phase I Clinical Trial of ANA773 in Cancer Patients
11. Anadys Pharmaceuticals to Present at the Cowen and Company Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... and BETHESDA, Md. , Jan. 14, ... with two institutes from the National Institutes of Health ... bringing safer, more effective treatments to patients on a ... for Advancing Translational Sciences (NCATS) and the National Eye ...
(Date:1/14/2014)... 2014 Global Record Systems, LLC, ... technology solutions for patients, physicians, the biopharmaceutical industry, ... today the signing of a three-year Research Collaboration ... Administration (FDA). This initiative is designed to ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , PLEASANTON, Calif., Sept. 1 Thoratec Corporation ... circulatory support therapies to save, support and restore failing hearts, said ... & Co. Healthcare Conference on Wednesday, September 9. , , ... officer, will provide an update on the company beginning at 10 ...
... BALTIMORE, Sept. 1 Champions Biotechnology, Inc. ... development of advanced preclinical platforms and tumor specific data to ... agreement with a large biotechnology company for the evaluation of ... , , By maintaining the fundamental genotypic ...
... , , TUSTIN, Calif., Sept. 1 ... management will present at the Rodman & Renshaw 11th Annual Healthcare Conference ... will be held at the New York Palace Hotel in New York ... presentation will be available at the Investors section of Peregrine,s website at ...
Cached Biology Technology:Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 2Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader 3Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference 2
(Date:4/17/2014)... detection cartridge developed at Sandia National Laboratories and recently ... faster and cheaper. , Bacillus anthracis , ... soils all over the world and can cause serious, ... The bacteria can survive in harsh conditions for decades. ... occur through skin contact, inhalation of spores or eating ...
(Date:4/17/2014)... in bone marrow need to produce hydrogen sulfide in ... to a new study from the Center for Craniofacial ... of USC. , Professor Songtao Shi, principal investigator on ... by the cells governs the flow of calcium ions. ... that results in osteogenesis, or the creation of new ...
(Date:4/17/2014)... honeybees in Europe, Asia and the United States are ... be impacting native honeybee populations at this time, according ... include including Nosema microsporidia and Varroa ... resilient to these invasive pests, which suggests to us ... Asia and the United States currently are not necessary ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3East African honeybees are safe from invasive pests… for now 2East African honeybees are safe from invasive pests… for now 3
... to develop new drugs, the pharmaceuticals industry is making ... natural biological transformation processes. One of the most important ... a bioreactor filled with a liquid culture medium. As ... conditions inside the bioreactor need to be monitored precisely. ...
... disciplines recently gathered to address a major question: what ... Of course, possible answers to this question raise even ... to alter local vegetation, how would this new landscape ... certainty would allow us to manage better our natural ...
... BioScience, researchers present a sophisticated new analysis ... on greenhouse gas emissions. The study, conducted by Thomas ... on how mandated increases in production of the biofuel ... and elsewhere. In response to the increased demand for ...
Cached Biology News:Clean sampling from bioreactors 2Networking initiative to support interdisciplinary research 2Networking initiative to support interdisciplinary research 3More maize ethanol may boost greenhouse gas emissions 2
... a proteolytic product of ... I which retains polymerization and ... but has lost 5 ->3 ... polymerization fidelity of the holoenzyme ...
... RNase H degrades, as an endoribonuclease, ... DNA hybrids of natural origin, e.g. ... synthetic complexes, e.g. poly(A) x poly(dT). ... and 3-OH termini. Nearly no activity ...
... E. coli strain containing an overproducing clone of ... the formation of a phosphodiester bond between juxtaposed ... DNA or RNA. It repairs single-stranded nicks in ... join both blunt-end and cohesive-end fragments of duplex ...
Goat polyclonal to Haptoglobin ( Abpromise for all tested applications). Antigen: Affinity purified human haptoglobin. Entrez GeneID: 3240 Swiss Protein ID: P00738...
Biology Products: